Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ayrton L. Goddard"'
Autor:
Tamer B Shabaneh, Sondra L Downey, Ayrton L Goddard, Michael Screen, Marcella M Lucas, Alan Eastman, Alexei F Kisselev
Publikováno v:
PLoS ONE, Vol 8, Iss 2, p e56132 (2013)
The proteasome inhibitor bortezomib (Velcade) is prescribed for the treatment of multiple myeloma. Clinically achievable concentrations of bortezomib cause less than 85% inhibition of the chymotrypsin-like activity of the proteasome, but little atten
Externí odkaz:
https://doaj.org/article/d150bdbd6bd641dda9f8a08422b25fc4
Autor:
Alexei F. Kisselev, Michael Screen, Alan Eastman, Tamer B. Shabaneh, Marcella M. Lucas, Sondra L. Downey, Ayrton L. Goddard
Publikováno v:
PLoS ONE, Vol 8, Iss 2, p e56132 (2013)
PLoS ONE
PLoS ONE
The proteasome inhibitor bortezomib (Velcade) is prescribed for the treatment of multiple myeloma. Clinically achievable concentrations of bortezomib cause less than 85% inhibition of the chymotrypsin-like activity of the proteasome, but little atten
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58499578530d0f4309ab111af9dbc24c
http://europepmc.org/articles/PMC3584083?pdf=render
http://europepmc.org/articles/PMC3584083?pdf=render
Autor:
Michael Screen, Marcella M. Lucas, Alexandre A. Pletnev, Robert Tokhunts, Dennis L. Wright, Omar Amir, Matthew Britton, Herman S. Overkleeft, Martijn Verdoes, Ayrton L. Goddard, Sondra L. Downey, Alexei F. Kisselev, Philip M. Pelphrey
Publikováno v:
Chemistrybiology. 16(12)
Proteasomes degrade most proteins in mammalian cells and are established targets of anti-cancer drugs. All eukaryotic proteasomes have three types of active sites: chymotrypsin-like, trypsin-like, and caspase-like. Chymotrypsin-like sites are the mos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36a80c2ee9d34929f39396358c7ebb1c
https://pubmed.ncbi.nlm.nih.gov/20064438
https://pubmed.ncbi.nlm.nih.gov/20064438